Salarius Pharmaceuticals Stock (NASDAQ: SLRX)

Salarius Pharmaceuticals (NASDAQ:SLRX) Stock, Quote.Headers.trade-ideas

Salarius Pharmaceuticals

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Movers

News

Intraday Update

Markets

Trading Ideas

ASTS

ATPC

BALY

BLMZ

CERO

COOP

CTNT

EZFL

FORM

GSHD

HOTH

INDV

JBHT

KALU

KDLY

LULU

PEGA

PLXS

POAI

RBBN

SHYF

SLGL

SLNA

SLRX

STLA

TIVC

TWOU

VKTX

XCUR

Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Wall Street US stocks

Earnings

Eurozone

Commodities

Dow Jumps 200 Points; Honeywell Trims Profit Outlook

xr:d:DAFp1nJl8vk:2,j:4184241900145690738,t:23072714

ADIL

AEVA

AROC

AZTR

CGBS

CLRB

CMAX

CMCSA

DRMA

EFSH

FEIM

FLYE

FTEL

ICLK

JAGX

KNSA

MEDP

MESO

MIRA

MLSS

MMYT

MSCI

NCPL

NUKK

NXPI

PCAR

PSIG

RNAZ

SMFL

SOAR

SPOT

STAF

TUSK

WBTN

ZION

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals GAAP EPS of -$3.84

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) just reported results for the fourth quarter of 2023.<ul><li>Salarius Pharmaceuticals reported earnings per share of -22 cents. This was above the analyst estimate for EPS of -$1.01.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/slrx-stock-earnings-salarius-pharmaceuticals-for-q4-of-2023/">SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers that traders need to know about on Monday morning!



Moving stocks this morning are cannabis legalization, drug approval, a delisting update and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Next e GO (NASDAQ:<a href="https://investorplace.com/stock-quotes/egox-stock-quote/">EGOX</a>) stock is rocketing more than 127% alongside heavy pre-market trading this morning.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) shares are soaring close to 54% with strong early morning trading today.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) stock is surging over 28% following the release of its <a href="https://www.nasdaq.com/press-release/salarius-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results">latest earnings report</a>.</li>



<li>Canopy Growth (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgc-stock-quote/">CGC</a>) shares are gaining 16% following <a href="https://www.nasdaq.com/press-release/canopy-growth-celebrates-passage-of-cannabis-legalization-in-germany-2024-03-22">cannabis legalization in Germany</a>.</li>



<li>Cazoo (NYSE:<a href="https://investorplace.com/stock-quotes/czoo-stock-quote/">CZOO</a>) stock is increasing more than 15% without any clear news this morning.</li>



<li>Flora Growth (NASDAQ:<a href="https://investorplace.com/stock-quotes/flgc-stock-quote/">FLGC</a>) shares are rising over 15% alongside cannabis legalization in Germany.</li>



<li>Esperion Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/espr-stock-quote/">ESPR</a>) stock is climbing more than 14% <a href="https://www.msn.com/en-us/money/markets/esperion-therapeutics-masimo-and-other-big-stocks-moving-higher-in-monday-s-pre-market-session/ar-BB1kuixT">following approval from the</a> Food and Drug Administration (FDA).</li>



<li>Forge Global (NYSE:<a href="https://investorplace.com/stock-quotes/frge-stock-quote/">FRGE</a>) shares are heading more than 14% higher ahead of its <a href="https://www.defenseworld.net/2024/03/24/forge-global-frge-to-release-earnings-on-tuesday.html">upcoming earnings report tomorrow</a>.</li>



<li>Nkarta (NASDAQ:<a href="https://investorplace.com/stock-quotes/nktx-stock-quote/">NKTX</a>) stock is jumping over 13% after <a href="https://www.nasdaq.com/press-release/nkarta-announces-pricing-of-%24240-million-underwritten-offering-2024-03-25">pricing an underwritten offering</a>.</li>



<li>Masimo (NASDAQ:<a href="https://investorplace.com/stock-quotes/masi-stock-quote/">MASI</a>) shares are up nearly 12% alongside <a href="https://www.nasdaq.com/press-release/politan-nominates-two-independent-candidates-for-masimo-board-2024-03-25">Board seat nominations</a>.</li>
</ol><h2>Top 10 Losers</h2><ol></ol><ol><li>MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038 (NYSEARCA:<a href="https://investorplace.com/stock-quotes/fngd-stock-quote/">FNGD</a>) stock appears to be crashing almost 90% but it&rsquo;s actually <a href="https://finance.yahoo.com/news/bmo-announces-reverse-split-three-211500378.html">undergoing a reverse stock split today</a>.</li>



<li>Trxade Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/meds-stock-quote/">MEDS</a>) shares are plummeting more than 35% on Monday morning.</li>



<li>Sintx Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sint-stock-quote/">SINT</a>) stock is diving close to 34% after announcing a <a href="https://www.nasdaq.com/press-release/sintx-technologies-announces-proposed-public-offering-of-common-stock-2024-03-22">proposed public offering</a>.</li>



<li>Joann (NASDAQ:<a href="https://investorplace.com/stock-quotes/joan-stock-quote/">JOAN</a>) shares are decreasing over 16% as it <a href="https://www.streetinsider.com/8K/JOANN+Inc+%28JOAN%29+Stock+to+Be+Delisted+on+March+28th/22969264.html">prepares to be delisted</a>.</li>



<li>Murano Global Investments (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrno-stock-quote/">MRNO</a>) stock is dropping nearly 15% <a href="https://investorplace.com/2024/03/why-is-murano-global-mrno-stock-up-over-130-today/">following a recent rally</a>.</li>



<li>Virios Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/viri-stock-quote/">VIRI</a>) shares are tumbling more than 12% after a Friday rally.</li>



<li>Movella (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvla-stock-quote/">MVLA</a>) stock is taking an over 12% beating after <a href="https://www.nasdaq.com/press-release/movella-announces-appointment-of-marcum-llp-as-new-independent-registered-public">climbing on Friday</a>.</li>



<li>IMAC (NASDAQ:<a href="https://investorplace.com/stock-quotes/back-stock-quote/">BACK</a>) stock is falling more than 11% after a massive Friday rally.</li>



<li>Aurora Mobile (NASDAQ:<a href="https://investorplace.com/stock-quotes/jg-stock-quote/">JG</a>) shares are sliding more than 11% after announcing plans to <a href="https://www.nasdaq.com/press-release/aurora-mobiles-gptbots.ai-to-team-up-with-moonshot-ai-2024-03-25">team up with Moonshot AI</a>.</li>



<li>Australian Oilseeds (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOT#NASDAQ">COOT</a>) stock closes out our pre-market stock movers down over 10% following its <a href="https://www.graincentral.com/news/australian-oilseeds-debuts-on-nasdaq/">public debut on Friday</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-march-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) just reported results for the first quarter of 2024.<ul><li>Salarius Pharmaceuticals reported earnings per share of -41 cents. This was above the analyst estimate for EPS of -$6.70.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/slrx-stock-earnings-salarius-pharmaceuticals-for-q1-of-2024/">SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024

Salarius Pharmaceuticals to effect 1-for-8 reverse stock split to regain Nasdaq compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Thursday and we have breakdowns of all the latest news sending shares higher and lower this morning!



Moving stocks this morning are share sales, a new order, a closed public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Blue Star Foods (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsfc-stock-quote/">BSFC</a>) stock is rocketing more than 67% alongside heavy pre-market trading.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) shares are surging over 67% after UBS Group AG (NYSE:<a href="https://investorplace.com/stock-quotes/ubs-stock-quote/">UBS</a>) <a href="https://www.benzinga.com/news/24/07/39725326/ev-maker-volcons-stock-skyrockets-over-70-in-pre-market-following-ubs-groups-buy-sell-transactions">bought and sold shares</a>.</li>



<li>CNS Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) stock is soaring more than 51% alongside strong early morning trading.</li>



<li>MingZhu Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ygmz-stock-quote/">YGMZ</a>) shares are gaining over 42% with strong pre-market trading today.</li>



<li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is heading more than 30% higher on a <a href="https://www.nasdaq.com/press-release/actelis-receives-260000-order-major-mid-atlantic-us-county-traffic-system">traffic system order</a>.</li>



<li>Phoenix Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/pev-stock-quote/">PEV</a>) shares are increasing over 18% despite a lack of news this morning.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock is climbing more than 17% as it <a href="https://investorplace.com/2024/07/why-is-kazia-therapeutics-kzia-stock-up-300-today/">continues a recent rally</a>.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares are rising close to 16% with heavy early morning trading.</li>



<li>Staffing 360 Solutions (NASDAQ:<a href="https://investorplace.com/stock-quotes/staf-stock-quote/">STAF</a>) stock is jumping over 13% on Thursday without any clear news.</li>



<li>Naas Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/naas-stock-quote/">NAAS</a>) shares are up 13% as part of an ongoing rally.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is plummeting more than 33% without any apparent news this morning.</li>



<li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) shares are diving over 27% on Thursday.</li>



<li>Inspire Veterinary (NASDAQ:<a href="https://investorplace.com/stock-quotes/ivp-stock-quote/">IVP</a>) stock is tumbling more than 26% after <a href="https://www.nasdaq.com/press-release/inspire-veterinary-partners-announces-closing-6-million-public-offering-2024-07-10">closing a public offering</a>.</li>



<li>Quhuo (NASDAQ:<a href="https://investorplace.com/stock-quotes/qh-stock-quote/">QH</a>) shares are taking an over 19% beating after a recent rally.</li>



<li>Cingulate (NASDAQ:<a href="https://investorplace.com/stock-quotes/cing-stock-quote/">CING</a>) stock is sliding more than 18% following a surprise rally yesterday.</li>



<li>Next Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxtt-stock-quote/">NXTT</a>) shares are dropping over 16% on Thursday morning.</li>



<li>Janover (NASDAQ:<a href="https://investorplace.com/stock-quotes/jnvr-stock-quote/">JNVR</a>) stock is decreasing more than 15% <a href="https://www.nasdaq.com/press-release/janovers-new-insurtech-platform-launches-do-liability-insurance-publicly-traded">after climbing higher yesterday</a>.</li>



<li>Zapp Electric Vehicles (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/">ZAPP</a>) shares are slipping over 14% as it <a href="https://investorplace.com/2024/07/why-is-zapp-electric-vehicles-zapp-stock-down-25-today/">continues to retreat</a>.</li>



<li>Telesis Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbio-stock-quote/">TBIO</a>) stock is dipping nearly 14% after a similar rise yesterday.</li>



<li>SAI.TECH Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/sai-stock-quote/">SAI</a>) shares close out our pre-market stock movers down more than 13% <a href="https://www.nasdaq.com/press-release/saitech-announces-mou-signings-heatnuc-targeting-nuclear-and-smr-markets-middle-east">following a rally yesterday</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-11th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Friday as we check out all of the latest stories affecting shares on the last day of trading this week!



Moving stocks this morning are a Maui fire settlement report, a reverse stock split notice, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) stock is rocketing more than 68% with heavy trading after announcing <a href="https://www.nasdaq.com/press-release/presentation-times-and-schedule-participating-companies-now-posted-conference-website">a presentation yesterday</a>.</li>



<li>60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) shares are soaring over 37% alongside strong early morning trading.</li>



<li>Hawaiian Electric Industries (NYSE:<a href="https://investorplace.com/stock-quotes/he-stock-quote/">HE</a>) stock is surging more than 37% on reports it included in the <a href="https://finance.yahoo.com/news/hawaiian-electric-among-firms-4-212211492.html">Maui fire settlement</a>.</li>



<li>Power REIT (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pw-stock-quote/">PW</a>) shares are increasing over 23% without any apparent news.</li>



<li>Safe &amp; Green Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/">SGD</a>) stock is gaining more than 23% with strong pre-market trading.</li>



<li>Novo Integrated Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvos-stock-quote/">NVOS</a>) shares are rising over 22% on a <a href="https://www.businesswire.com/news/home/20240718621664/en/Novo-Integrated-Sciences-Receives-Commencement-of-Disbursement-Notice-for-SBLC-Leasing-and-Monetizing-Program">disbursement funds notice</a>.</li>



<li>Unicycive Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/uncy-stock-quote/">UNCY</a>) stock is climbing more than 15% despite a lack of news this morning.</li>



<li>Talphera (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlph-stock-quote/">TLPH</a>) shares are heading over 13% higher without any clear news to report.</li>



<li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is jumping close to 13% on Friday morning.</li>



<li>Sobr Safe (NASDAQ:<a href="https://investorplace.com/stock-quotes/sobr-stock-quote/">SOBR</a>) shares are up more than 12% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) stock is diving over 19% after <a href="https://www.prnewswire.com/news-releases/nauticus-robotics-announces-transformative-1-for-36-reverse-stock-split-302201004.html">announcing a reverse stock split</a>.</li>



<li>SunPower (NASDAQ:<a href="https://investorplace.com/stock-quotes/spwr-stock-quote/">SPWR</a>) shares are tumbling more than 17% after <a href="https://finance.yahoo.com/news/sunpower-plunges-halting-solar-installs-180816388.html">halting some of its operations</a>.</li>



<li>WaveDancer (NASDAQ:<a href="https://investorplace.com/stock-quotes/wavd-stock-quote/">WAVD</a>) stock is taking a nearly 14% beating on Friday morning.</li>



<li>CrowdStrike (NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>) shares are sliding over 13% <a href="https://www.cnbc.com/2024/07/19/crowdstrike-suffers-major-outage-affecting-businesses-around-the-world.html">alongside outages and issues</a>.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) stock is dropping more than 11% <a href="https://www.nasdaq.com/press-release/bionomics-initiates-affirm-1-phase-3-clinical-trial-bnc210-social-anxiety-disorder">following clinical trial results yesterday</a>.</li>



<li>Scholastic (NASDAQ:<a href="https://investorplace.com/stock-quotes/schl-stock-quote/">SCHL</a>) shares are decreasing over 11% with its <a href="https://www.benzinga.com/news/earnings/24/07/39849856/scholastic-shares-fall-after-worse-than-expected-q4-results-details">fiscal Q4 earnings report</a>.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) stock is falling more than 10% after a major rally yesterday.</li>



<li>HighPeak Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/hpkew-stock-quote/">HPKEW</a>) shares are slipping over 10% this morning.</li>



<li>Super League Enterprise (NASDAQ:<a href="https://investorplace.com/stock-quotes/sle-stock-quote/">SLE</a>) stock is dipping almost 10% today.</li>



<li>CytoMed Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdtc-stock-quote/">GDTC</a>) shares are down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-19th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Genomic therapeutic specialist Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) screamed higher Tuesday, with shares gaining 160% before paring back some of the gains to around 90%. Although no catalyst is apparent, the biotechnology firm revealed details about its at-the-market (ATM) offering recently. Likely, investors are speculating on SLRX stock that an improvement in funding is the main obstacle obstructing its therapeutic goals.



According to the company&rsquo;s website, Salarius specializes in gene dysregulation therapeutic research. The biotech notes that in certain cancers, &ldquo;the proteins that regulate gene expression become dysregulated. They may incorrectly turn cancer-promoting genes on and cancer-suppressing genes off, which can lead to disease development and progression.&rdquo;



To combat this undesirable dynamic, Salarius has developed two classes of drugs that address this dysregulation: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). Presently, the company is in the early clinical stages of research and development.



<h2>SLRX Stock May Receive a Financial Lifeline</h2>



According to an <a href="https://investors.salariuspharma.com/static-files/d2501a7d-e16f-4487-a379-1e965920eed2">amendment to its S-3 document</a> filed with the U.S. Securities and Exchange Commission (SEC), Salarius revealed that on July 9, it received a notification from researchers at the University of Texas MD Anderson Cancer Center (MDACC) that a patient in the center&rsquo;s sponsored clinical trial evaluating one of the biotech&rsquo;s therapeutics suffered a serious and unexpected adverse reaction.



Per the standardized procedure, the entities notified the U.S. Food and Drug Administration (FDA). Subsequently, the regulatory agency requested that MDACC put the aforementioned clinical trial on hold. Salarius intends to support MDACC researchers in analyzing available data and responding to FDA-submitted questions.



On a separate matter, on July 19, Salarius decided to close its ongoing Phase 1/2 clinical trial in an effort to preserve cash. The statement also mentioned that the board of directors was looking to explore potential strategic alternatives.



In the same amendment document, management revealed that it entered into an ATM offering with Ladenburg Thalmann, an investment bank. Under the terms of the agreement, Salarius has the potential to raise up to $810,973 in additional capital.



It&rsquo;s possible that speculators pumped money into SLRX stock in anticipation that Salarius may receive this financial lifeline.



<h2>Risky but Somewhat Sensible Wager</h2>



It cannot be stressed enough that SLRX stock is a speculative entity. Even with the blistering run today, the market capitalization sits at less than $2 million. However, because of the modest valuation, an influx of nearly $1 million could shift the paradigm. That may also be what speculators are thinking.



To be sure, the broader genomics sector is a compelling one. According to Grand View Research, the global ecosystem <a href="https://www.grandviewresearch.com/industry-analysis/genomics-market">reached a valuation of $32.65 billion last year</a>. Experts project that the segment could expand at a compound annual growth rate (CAGR) of 16.5% from 2024 to 2030. At the forecast culmination point, the genomics market could be worth $94.86 billion.



For context, the global biotech market hit a valuation of $1.55 trillion last year. However, the <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">anticipated CAGR from 2024 to 2030 is 13.96%</a>, meaning that there is a higher percentage growth opportunity in the genomics segment. This framework, too, could be playing a role in the rise of SLRX stock today.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-salarius-pharmaceuticals-slrx-stock-up-90-today/">Why Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news to start the day with!



Moving stocks this morning a partnerships, a public offering, clinical trial news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rocketing more than 123% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring over 75% with strong early morning trading.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is surging more than 45% <a href="https://www.nasdaq.com/press-release/hoth-therapeutics-partners-lts-therapy-systems-accelerate-novel-alzheimers-treatment">on a new partnership</a> to develop its Alzheimer&rsquo;s treatment.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are increasing over 44% after encouraging investors to <a href="https://finance.yahoo.com/news/allarity-encourages-shareholders-vote-reverse-100000785.html">vote for a reverse stock split</a>.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is heading more than 33% higher alongside strong pre-market trading.</li>



<li>Pieris Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pirs-stock-quote/">PIRS</a>) shares are rising over 28% after <a href="https://www.nasdaq.com/press-release/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement">announcing a merger agreement</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is jumping more than 23% with heavy early morning trading today.</li>



<li>NewGenIvf (NASDAQ:<a href="https://investorplace.com/stock-quotes/nivf-stock-quote/">NIVF</a>) shares are climbing over 22% after providing a <a href="https://www.nasdaq.com/press-release/newgenivf-provides-update-potential-reverse-merger-covirix-2024-07-23">reverse merger update</a>.</li>



<li>Perfect Moment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/">PMNT</a>) stock is getting a close to 19% boost after announcing a <a href="https://www.nasdaq.com/press-release/perfect-moment-teams-quiet-platforms-establish-distribution-center-us-2024-07-22">distribution center agreement</a>.</li>



<li>Catheter Precision (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vtak-stock-quote/">VTAK</a>) shares are up more than 16% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is crashing over 73% but only <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">after a massive rally yesterday</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are plummeting 28% on <a href="https://www.12newsnow.com/article/news/local/texas/conns-reportedly-planning-mass-closures/502-4db60564-6fdd-4ffa-ae26-899bec91f75c">reports of impending store closures</a>.</li>



<li>ATI Physical Therapy (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/">ATIP</a>) stock is diving more than 25% without any obvious news this morning.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are tumbling over 25% on a <a href="https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200500583.html">proposed public offering</a>.</li>



<li>Agape ATP (NASDAQ:<a href="https://investorplace.com/stock-quotes/atpc-stock-quote/">ATPC</a>) stock is taking an almost 24% beating after a rally yesterday.</li>



<li>AtlasClear (NYSEMKT:<a href="https://investorplace.com/stock-quotes/atch-stock-quote/">ATCH</a>) shares are sliding more than 22% despite a lack of news on Wednesday.</li>



<li>Sage Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/sage-stock-quote/">SAGE</a>) stock is dropping over 22% after reporting <a href="https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-topline-results-phase-2-kinetic-2-study-sage">Phase 2 topline results</a>.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) shares are decreasing more than 21% <a href="https://www.nasdaq.com/press-release/volato-updates-fractional-program-additional-differentiated-benefits-2024-07-23">after a recent rally</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) stock is slipping over 19% following yesterday&rsquo;s rally.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares close out our pre-market stock movers down more than 19% after a rally yesterday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) just reported results for the second quarter of 2024.<ul><li>Salarius Pharmaceuticals reported earnings per share of -$2.37. This was above the analyst estimate for EPS of -$53.60.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/slrx-stock-earnings-salarius-pharmaceuticals-for-q2-of-2024/">SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q2 2024

ALLR

ASNS

ATCH

ATIP

BACK

BBLG

BNOX

BSFC

CING

CJET

CNSP

CONN

COOT

CRWD

CZOO

EGOX

ESPR

FLGC

FNGD

FRGE

GDTC

HPKEW

JNVR

JOAN

KITT

KZIA

MASI

MEDS

MLGO

MRNO

MVLA

NAAS

NIVF

NKTX

NUZE

NVOS

NXTT

PIRS

PMNT

SAGE

SCHL

SERV

SINT

SOBR

SPWR

SXTP

TBIO

TLPH

UNCY

VIRI

VLCN

VSTM

VTAK

WAVD

WRNT

YGMZ

ZAPP

Health Care

Press Releases

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Salarius Pharmaceuticals

Salarius Pharmaceuticals (SLRX) Forecast

Salarius Pharmaceuticals (NASDAQ:SLRX) Stock, Quote.Headers.trade-ideas